Business
Team USA medical staff have first official Olympic uniform
![](https://i2.wp.com/fortune.com/img-assets/wp-content/uploads/2024/07/savannah-mohamed-duo-1.jpg?resize=1200,600&w=1200&resize=1200,0&ssl=1)
The Summer Olympics are nothing if not an amalgam of highs and lows for the world’s best athletes. They weather wins and wipeouts, pride and pain, shattered records and shattered bones. As Team USA Olympians and Paralympians take the stage in Paris in the coming weeks, medical staff will be there to support every feat and fall—in style.
For the first time, the more than 250 health care professionals who form the Team USA Medical Team have a uniform. Figs, a direct-to-consumer medical apparel brand—and the first company led by two female cofounders to go public—partnered with the U.S. Olympic and Paralympic Committee (USOPC) to break another barrier.
“This is the first time ever that a medical team has been outfitted for any country for the Olympic Games,” Figs cofounder and CEO Trina Spear tells Fortune. “It’s very much about something that speaks to our overall mission and values as a company from day one: putting health care professionals in the spotlight that they deserve. Usually they’re behind the scenes, but not anymore. This is really about showcasing the people who are serving all of us, serving humanity, and in this case, serving athletes.”
When Spear and Figs cofounder Heather Hasson broached the idea with the USOPC, they were surprised to learn that not only did the Team USA medical staff lack a single outfitter, they also were responsible for their own dress at the Games. The committee, Spear says, was just as eager to find a way to lift up the health care workers who help keep Olympians and Paralympians at the top of their game.
“They act as a team, supporting all the athletes. They should be outfitted as a team,” Spear says. “It’s historic for them as well.”
Team USA medical staff are just as excited about their Olympic threads as Figs was to create them, Spear says. Dr. Gloria Beim, a Colorado-based orthopedic surgeon who has been a Team USA physician since the 2004 Summer Olympics in Athens, is grateful for the company’s backing.
![Dr. Benedict I. (left), a primary care and sports medicine physician, and Amarilees B., an athletic trainer, wear Team USA Medical Team gear designed by Figs. More than 250 health care professionals will wear the uniforms at the 2024 Summer Olympics and Paralympics in Paris.](https://fortune.com/img-assets/wp-content/uploads/2024/07/benedict-amo-duo-1-e1721241108993.jpg?w=1440&q=75)
Courtesy of Figs
“When I was first approached by Figs about this partnership, my immediate thought was, ‘What an amazing opportunity to spotlight health care professionals, especially post-COVID,’” Beim said in a statement exclusive to Fortune. “As a surgeon in a small town, I see my patients outside of the hospital and feel their appreciation regularly. However, my colleagues across the country don’t all get that level of respect for the work that they do every single day.
“What most people don’t understand is the level of training and sacrifice that goes into becoming a health care professional. And it’s not just our own lives impacted, but our loved ones as well. There’s nothing that fills my soul more than helping people.”
Stars, stripes, and stethoscopes
This isn’t Figs’ first foray into professional sports medicine—the company already outfits medical staff caring for the English Premier League’s Everton Football Club—but it marks the company’s biggest marketing maneuver. Its multiyear deal with the USOPC extends through the 2028 Summer Olympic and Paralympic Games in Los Angeles.
Figs kicked off its campaign Thursday with a video ad called “Anatomy of a Champion.” The tagline: “It takes heart to build bodies that break records.” Set to the tune of the anatomic children’s song “Heads, Shoulders, Knees, and Toes,” the video showcases 14 health care professionals and half a dozen athletes, current and former Olympians and Paralympians included. Medical staff, of course, are sporting the limited-edition Figs x Team USA Medical Team scrubs.
Coming in solid cherry red, optic white, and navy blue, the scrubs are clean-cut and practical. Simple touches, like a jumpsuit for women and a high collar for men, add a futuristic vibe. The medical staff modeling the apparel in promotional photos look like they’re on a mission, which they are.
“It goes back to what we’ve always done, really a focus on function,” Spear tells Fortune. “We have a pocketing architecture for everything we create—where you put your stethoscope, your alcohol swabs, your sutures, your stitches, your wraps, all your tapes—everything that you need to perform at your best.”
Spear adds, “It’s pretty awesome that Figs creates pockets and zippers for people to hold the tool that will save someone’s life. That intention has always been a part of what we do. And, in this case, it’s on a global stage [so] we had to get it right.”
![Dr. Adam C. (left), an emergency medicine physician, and Dr. Julia I., a sports medicine physician, wear Team USA Medical Team gear designed by Figs. More than 250 health care professionals will wear the uniforms at the 2024 Summer Olympics and Paralympics in Paris.](https://fortune.com/img-assets/wp-content/uploads/2024/07/adam-julia-duo-1-e1721241364544.jpg?w=1440&q=75)
Courtesy of Figs
Comfort was also top of mind in designing the apparel for health care workers, says Spear, who envisioned them going from surgical suites to Olympic sidelines. The scrubs are meant to be streamlined, breathable, and unifying.
“Everyone [needs] health care professionals to ensure that we all can live healthy and prosperous lives, whether you’re an athlete winning a gold medal on that podium, or somebody who’s getting a mental health exam or a gynecological exam,” Spear says. “Health care professionals keep our bodies going, and that’s our goal—to celebrate them and make sure that they get a podium of their own.”
If you’re feeling patriotic, you don’t have to be an Olympic health care provider to don the Team USA Medical Team uniform; gear is available for purchase on the Figs website.
For more on the 2024 Summer Olympics and Paralympics in Paris:
Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.
Business
Denmark gets Novo Nordisk to lower Ozempic prices
![](https://i0.wp.com/fortune.com/img-assets/wp-content/uploads/2024/08/GettyImages-ozempic-e1723039257150.jpg?resize=1200,600&w=1200&resize=1200,0&ssl=1)
On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.
What Sanders didn’t realize was that Denmark, a country of 6 million, was enduring its own crisis over how to pay for the Novo Nordisk drugs Ozempic and Wegovy.
Most other developed countries, including Denmark, negotiate down drug costs for their citizens, paying prices that are a fraction of those in the United States. But when a drug is effective and expensive, pharmaceutical companies can play hardball on pricing. And Novo Nordisk did, at least initially, pushing the Danish health system to its limits.
The country’s socialized health system had for years covered Ozempic as a diabetes treatment, but in 2022 doctors began prescribing it for weight loss, too, and soon they “emptied all the money boxes in the entire public health system,” said University of Copenhagen professor Jens Juul Holst, a co-inventor of the drug.
Countries around the world are struggling with how and when to pay for Ozempic, Eli Lilly’s Mounjaro, and other drugs in the same chemical class, particularly when they are prescribed for weight loss. Indeed, the sky-high prices paid in the U.S. set a bar that pharmaceutical companies can use as they negotiate with other health systems.
In Denmark, with prescriptions for the drugs gobbling up 18% of regional drug budgets in 2023, officials were considering the unthinkable in a system that prides itself on free cradle-to-grave coverage: forcing patients to pay out-of-pocket for Ozempic — a drug made in the country.
In America, meanwhile, tightening insurance policies are making it harder for patients to get the drugs, which are listed at up to $1,350 a month.
“There are changes month to month in our clinic in terms of the supply, coverage, which drug is available,” said Michael Blaha, director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. He said that doctors and patients were “playing a constant game of prior authorization and appeals.”
In particular, use of the drugs for weight loss is a hot-button issue. Novo Nordisk and Lilly are battling for coverage — joined by some doctors and patient advocate groups, many funded by the drug companies. They are pressing to overturn a 2005 federal rule that prohibits Medicare from reimbursing weight loss treatments.
“There’s a strong assumption that Medicare is going to cover these drugs for obesity treatment sooner or later,” said David Kim, an assistant professor of medicine and public health sciences at the University of Chicago. If Medicare pays, he added, commercial insurers will probably follow suit.
The impact on federal and commercial insurance budgets, he said, depends on three unanswered questions: How many people will eventually get the drugs? For how long will they take them? And at what price?
The potential Medicare market alone is enormous. In 2020 about 13.7 million Medicare beneficiaries, around a quarter of the total, were diagnosed as overweight or obese, according to Juliette Cubanski and Tricia Neuman, researchers at KFF, a health information nonprofit that includes KFF Health News. Assuming a 50% discount on a $1,300 monthly list price for Wegovy, that’s a $107 billion price tag. The entire federal share of Medicare Part D spending in 2024 was projected to be $120 billion.
Novo Nordisk spent $7.6 million lobbying Congress over the past 12 months, and lobbying disclosures show that most of that was to promote bills in the House and Senate to expand use of the GLP-1 drugs.
Pressure from drugmakers has been relentless. Pfizer, which has a GLP-1 drug in development, commissioned a white paper by consultancy Manatt arguing that Medicare law already allows payment for these anti-obesity drugs, since they have benefits beyond weight loss. Novo and other pharmaceutical companies have funded research that shows health care savings on chronic disease through use of the drugs.
But the Congressional Budget Office, whose judgments about the cost of such policies weigh heavily in whether they are eventually adopted, has yet to give a final opinion. In a March presentation, the office said it was “not aware of empirical evidence that directly links the use of anti-obesity medicines to reductions in other health care spending.”
Prime Therapeutics, a pharmacy benefit manager whose clients are employers that fund drug plans, released a study this year finding that only a third of patients put on a GLP-1 drug stayed on it for a full year. That means insurance coverage of the drugs could sometimes be a waste of money, said Patrick Gleason, Prime Therapeutics’ leader of research, since research shows that patients tend to gain the weight back after cessation.
That doesn’t completely surprise Holst, the Danish scientist, who said the GLP-1 drugs’ suppression of appetite is for many people “so miserably boring that you can’t stand it any longer and you have to go back to your old life.”
One answer might be weight loss programs that employ the GLP-1s for, say, a year, followed by maintenance therapy with cheaper drugs, Kim said.
One way or another, many experts in the field say, it’s sensible to cover weight loss before the onset of the chronic illnesses associated with obesity, like Type 2 diabetes.
Indeed, because obesity is associated with so many comorbidities, drugmakers are now doing studies showing that GLP-1 drugs also show positive impact on conditions like sleep apnea and heart, liver, and kidney diseases.
Yet even advocates for the drugs’ use acknowledge uncertainty about how long it would take for such health benefits to kick in, or whether shorter-term use would prevent or ameliorate longer-term illnesses.
“Modeling the impacts is complicated,” said Alison Sexton Ward, a research scientist at the University of Southern California’s Schaeffer Center for Health Policy and Economics. “Medical costs won’t go down immediately. The prevented diseases may be years in the future.”
Starting next year, Medicare beneficiaries’ Part D out-of-pocket costs will be capped at $2,000, meaning U.S. taxpayers will foot the bill for most Medicare drug expenses. So it’s no surprise the Congressional Budget Office believes the government will launch Medicare price negotiations for semaglutide under the Inflation Reduction Act “within the next few years,” per its March presentation.
According to the terms of the act, Ozempic would be eligible for government price negotiation as early as next year, with new prices reflected in 2027. The negotiated unit price would apply to all forms of the drug — Ozempic; its higher-dose, weight loss-branded version, Wegovy; and a pill, Rybelsus.
Where the price would land is unclear. Wegovy costs patients up to $365 a month in Denmark, which typically doesn’t cover the drug — and about $140 in Germany and $92 in the U.K.
Meanwhile, generic drugmakers are gearing up to sell their versions of semaglutide. Those appear set to go on sale in China and Brazil as early as 2026. Americans are likely to have to wait until at least 2032 because of U.S. patent restrictions. The Federal Trade Commission has tried to nibble at the drugs’ exclusivity periods by challenging Novo Nordisk patent filings on applicators used to inject the drugs — which would extend their market exclusivity up to 30 months.
For now, patients who can’t afford or access the drugs often turn to compounded forms, which are not FDA-approved although their raw material comes from FDA-registered factories. Blaha has “a number of patients” who can’t access the branded drugs and show up at the clinic with compound drug vials.
Two weeks before Sanders published his letter in Denmark, Novo Nordisk cut the local price of Ozempic by 34%, to $130 a month — about 15% of its U.S. list price. The government, which had warned it would stop paying for the drug, agreed to cover Ozempic diabetes treatment, but only for patients who had first tried a cheaper medicine such as metformin.
Wegovy, the same medicine but at a higher dose, targeted to weight loss, would in nearly all cases remain the patient’s responsibility at $365 monthly, a price that, while modest by U.S. standards, has sparked intense discussions about the uneven impact of class on its affordability, said Nils Jakob Knudsen, an endocrinologist in Copenhagen.
The calculus of the drugs’ price is complex for the Danes, he added, because “the blooming economy for Novo is also driving our very healthy Danish economy.”
Novo Nordisk’s market valuation of $591 billion on Aug. 2 was considerably higher than the entire GDP of Denmark.
Business
Weekly mortgage refinance demand soars 16% as rates sink to lowest level in over a year
![](https://i3.wp.com/image.cnbcfm.com/api/v1/image/107379313-1709073042993-gettyimages-1556374314-dji_0410_ukx1l6ut.jpeg?v=1721771811&w=1920&h=1080&w=1200&resize=1200,0&ssl=1)
An aerial view shows a subdivision that has replaced the once rural landscape in Hawthorn Woods, Illinois.
Scott Olson | Getty Images
Mortgage interest rates dropped last week to the lowest level since May 2023, causing a surge in mortgage demand from both homebuyers and especially current homeowners.
Total mortgage application volume rose 6.9% last week compared with the previous week according to the Mortgage Bankers Association’s seasonally adjusted index. Volume was at the highest level since January of this year.
The average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances ($766,550 or less) decreased to 6.55% from 6.82%, with points decreasing to 0.58 from 0.62 (including the origination fee) for loans with a 20% down payment.
“Mortgage rates decreased across the board last week…following doveish communication from the Federal Reserve and a weak jobs report, which added to increased concerns of an economy slowing more rapidly than expected,” said Joel Kan, MBA’s vice president and deputy chief economist in a release.
Applications to refinance a home loan, which are most sensitive to weekly rate changes, jumped 16% for the week and were 59% higher than the same week one year ago. While the percentage increases are large, they are still coming off a very small base. The vast majority of borrowers today have loans with rates below 5%. There are less than one million borrowers who can benefit from a refinance and shave at least 75 basis points off their current rate.
Applications for a mortgage to purchase a home increased just 1% for the week but were still 11% lower than the same week one year ago.
“Despite the downward movement in rates, purchase activity only saw small gains, with an increase in conventional purchase applications offset by decreases in government purchase applications. For-sale inventory is beginning to increase gradually in some parts of the country and homebuyers might be biding their time to enter the market given the prospect of lower rates,” added Kan.
Mortgage rates fell further to start this week, following a stock market rout Monday. They rose sharply again, however, on Tuesday following some more positive economic data.
“This is how things often play out when the bond market forces a quick move to extreme rate levels. For example, several of the biggest drops in daily mortgage rates have followed quick moves to long-term highs,” wrote Matthew Graham, chief operating officer at Mortgage News Daily.
Business
Further rate cuts could fuel house price rises, says Halifax
![](https://i1.wp.com/ichef.bbci.co.uk/news/1024/branded_news/d761/live/8e7058a0-547c-11ef-aebc-6de4d31bf5cd.jpg?w=1200&resize=1200,0&ssl=1)
Lower mortgage rates and more interest rate cuts could fuel a “modest” rise in house prices for the rest of this year, Halifax has said.
The mortgage lender’s prediction came after property prices increased marginally in July following a flat few months.
Halifax said recent mortgage rate drops were “encouraging” for first-time buyers, those moving along the housing ladder or those refinancing.
But it warned affordability challenges and lack of available properties still posed problems for buyers.
“Against the backdrop of lower mortgage rates and potential further [Bank of England] base rate reductions, we anticipate house prices to continue a modest upward trend throughout the remainder of this year,” Amanda Bryden, head of mortgages at Halifax said.
Last week the Bank of England lowered interest rates to 5% – the first cut since the start of the pandemic in March 2020.
The Bank’s rate dictates the cost of borrowing set by High Street banks and money lenders for the likes of mortgages and credit cards.
The UK’s largest lender said a typical property cost £291,268 in July, up more than £2,200 compared to the previous month.
-
African History5 years ago
A Closer Look: Afro-Mexicans 🇲🇽
-
African History7 months ago
Black History Facts I had to Learn on My Own pt.6 📜
-
African History5 years ago
A Closer Look: Afro-Mexicans 🇲🇽
-
African History1 year ago
Major African Tribes taken away during the Atlantic Slave Trade🌍 #slavetrade #africanamericanhistory
-
African History1 year ago
Cameroon 🇨🇲 World Cup History (1962-2022) #football #realmadrid #shorts
-
African History1 year ago
What did Columbus Find in 1493? 🤯🔥🔥 #history #civilization #mesoamerica #africa #kemet
-
African History7 months ago
Black History Inventors: Mary Kenner 🩸
-
African History1 year ago
Origin Of ‘Cameroon’ 🇨🇲😳#africa